Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia

(University of Colorado Anschutz Medical Campus) Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.